X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB SHASUN PHARMA UNICHEM LAB/
SHASUN PHARMA
 
P/E (TTM) x -33.3 123.9 - View Chart
P/BV x 0.7 8.5 8.5% View Chart
Dividend Yield % 2.3 0.2 1,003.6%  

Financials

 UNICHEM LAB   SHASUN PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
SHASUN PHARMA
Mar-14
UNICHEM LAB/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs38294 405.5%   
Low Rs23446 513.4%   
Sales per share (Unadj.) Rs116.3214.2 54.3%  
Earnings per share (Unadj.) Rs-18.95.3 -354.6%  
Cash flow per share (Unadj.) Rs-11.715.8 -74.2%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %1.61.4 113.5%  
Book value per share (Unadj.) Rs381.053.3 714.3%  
Shares outstanding (eoy) m70.3456.62 124.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.60.3 811.6%   
Avg P/E ratio x-16.313.1 -124.3%  
P/CF ratio (eoy) x-26.24.4 -593.8%  
Price / Book Value ratio x0.81.3 61.7%  
Dividend payout %-26.418.7 -141.0%   
Avg Mkt Cap Rs m21,6683,958 547.5%   
No. of employees `0002.3NA-   
Total wages/salary Rs m2,0062,164 92.7%   
Avg. sales/employee Rs Th3,587.8NM-  
Avg. wages/employee Rs Th880.0NM-  
Avg. net profit/employee Rs Th-583.7NM-  
INCOME DATA
Net Sales Rs m8,18012,127 67.5%  
Other income Rs m610229 266.0%   
Total revenues Rs m8,79012,356 71.1%   
Gross profit Rs m-1,3201,009 -130.8%  
Depreciation Rs m505594 85.1%   
Interest Rs m80415 19.3%   
Profit before tax Rs m-1,295230 -563.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20 733.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m33-73 -46.0%   
Profit after tax Rs m-1,331302 -440.5%  
Gross profit margin %-16.18.3 -194.0%  
Effective tax rate %-2.6-31.7 8.1%   
Net profit margin %-16.32.5 -653.1%  
BALANCE SHEET DATA
Current assets Rs m23,3186,884 338.7%   
Current liabilities Rs m4,6358,456 54.8%   
Net working cap to sales %228.4-13.0 -1,762.3%  
Current ratio x5.00.8 617.9%  
Inventory Days Days12262 197.6%  
Debtors Days Days121108 112.9%  
Net fixed assets Rs m8,1634,970 164.2%   
Share capital Rs m141113 124.2%   
"Free" reserves Rs m26,6602,875 927.3%   
Net worth Rs m26,8013,020 887.4%   
Long term debt Rs m31,817 0.2%   
Total assets Rs m31,89013,347 238.9%  
Interest coverage x-15.21.6 -976.7%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.30.9 28.2%   
Return on assets %-3.95.4 -73.0%  
Return on equity %-5.010.0 -49.6%  
Return on capital %-4.513.3 -34.1%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m4,3565,843 74.6%   
Fx outflow Rs m02,173 0.0%   
Net fx Rs m4,3563,669 118.7%   
CASH FLOW
From Operations Rs m-1,123398 -282.5%  
From Investments Rs m16,487-1,635 -1,008.4%  
From Financial Activity Rs m-8,8111,309 -673.3%  
Net Cashflow Rs m6,55271 9,202.2%  

Share Holding

Indian Promoters % 50.1 39.2 127.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 3.6 419.4%  
FIIs % 3.0 17.6 17.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 39.6 80.1%  
Shareholders   20,176 20,750 97.2%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare UNICHEM LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Nov 16, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS